Division of Sanofi
Latest From Bioverativ Inc.
Flagship Pioneering combined Torque Therapeutics and Cogen Immune Medicines, which have raised more than $220m, into Repertoire Immune Medicines with an autologous T-cell therapy being studied in a Phase I trial.
In CEO Paul Hudson's first earnings call at the company's helm, he said he has big goals for driving growth but a deeper strategic update will be outlined to investors on Dec. 10 in Cambridge, Mass.
Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Looking back at significantly sized acquisitions over just five years reveals that half of 2014’s acquisitions can already be judged as outright failures or, at best, questionable. But some lessons can be learned from dud deals.
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Biogen Idec Hemophilia Inc.
- Syntonix Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- Senior Management
John Greene, EVP, CFO
Tim Harris, PhD, DSc, EVP, R&D
- Contact Info
Phone: (781) 663-4400
225 Second Ave.
Waltham, MA 02451
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.